利培酮合并壮阳胶囊治疗对慢性精神分裂症患者认知功能及社会功能的影响

目的 探讨利培酮合并壮阳胶囊治疗对慢性精神分裂症患者认知功能、精神症状及社会功能的影响.方法 将200例符合美国精神障碍诊断与统计手册第4版诊断标准的慢性精神分裂症患者随机分为利培酮联合壮阳胶囊(研究组,100例)和联合安慰剂(对照组,100例)两组,观察时间均为8周.阳性症状量表(SAPS)、阴性症状量表(SANS)、威斯康星卡片分类测验(WCST)及社会功能缺陷量表(SDSS)作为疗效评价工具.结果 治疗第8周末,两组SAPS、SANS及SDSS评分均较基线降低,WCST指标中除研究组持续应答数外均获改善,差异均有统计学意义(P均<0.01);研究组SAPS、SANS评分的降低较对照组更为明显.与基线比较,研究组WCST分类数较基线增加-1.2±1.9,对照组增加-0.7±1.4;研究组正确应答数增加-10.5±16.3,对照组增加-5.3±16.9;研究组错误应答数降低15.3±25.9,对照组降低7.2±23.7;研究组概念化水平百分数增加-15.1±23.0,对照组增加-9.5±26.7.研究组SDSS评分较基线降低(6.3±4.5)分,对照组降低(4.9±3.9)分.组间上述各项比较,差异均有统计学意义(P<0.05或<0.01).结论 利培酮联合壮阳胶囊比单用利培酮治疗对慢性精神分裂症患者的认知功能、精神症状及社会功能的改善更为有效.

Effrects of Zhuangyang capsule added on risperidone on cognition and social function in chronic schizophrenic patients

Objective To evaluate the effects of Zhuangyang capsule added on risperidone on cognition, symptoms and social function in chronic schizophrenia patients. Methods All 200 chronic schizophrenic patients who met the DSM-1V criteria for schizophrenia were randomized to receive 8 week treatment with either Zhuangyang capsule (trial group, n = 100) or placebo (control group, n = 100) added on risperidone. The symptoms were assessed with measurement including the Scale for the Assessment of Positive Symptoms(SAPS) and Scale for the Assessment of Negative Symptoms(SANS) and the cognition was assessed with the Wisconsin Card Sorting Test (WCST), while the social function with the Social Disability Screening Schedule (SDSS). Results Significant within-group improvements were observed in SAPS,SANS, WCST (except perseveringly responses number of trial group) and SDSS in 2 groups at the endpoint of week 8 (all P <0.01). The improvement in SAPS and SANS in trial group were more than that in control group(P<0.01). There were significant differences between 2 groups in the improvements of WCST parameters from baseline to weeks 8, including number of completed categories trial group of (1.2 ± 1.9)versus control group of (0.7 ± 1.4)], right responses number (10.5 ± 16.3) versus (5.3 ± 16.9)],error responses number (15.3±25.9) versus (7.2±23.7)], conceptual level (15.1±23.0) versus (9.5±26.7)]and social function(6.3±4.5) versus (4.9±3.9)] (P<0.05 or<0.01). Conclusion The adjunct therapy of Zhuangyang Capsule to risperidone is effective in improvement of cognitive function, symptoms and social function in chronic schizophrenic patients.